Legacy effects of fibrate add‑on therapy in diabetic patients with dyslipidaemia

There are ‘legacy effects’ of fibrate add-on therapy on cardiovascular outcomes in patients with dyslipidaemia.

Read More

What is the optimal treatment for HF?

Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals. In South Africa, HF…

Read More

Specialist Forum July 2021 CPDs

Below you will find links to CPD articles produced for Specialist Forum‘s July 2021 issue.

Read More

Heart failure redefined

Three international cardiology societies have joined forces to develop a new universal definition and classification of heart failure (HF).1

Diabetic nephropathy complexities

Hypertension is common among patients with diabetes. Hypertension increases their risk of chronic kidney disease (CKD) onset and progression, as…

Efficacy of fixed-dose, triple therapy in essential hypertension

Hypertension is the leading cause of mortality worldwide, accounting for more than 10 million deaths every year. The majority of…

Alirocumab reduces CVD risk in patients who fail to achieve LDL-C goals

The prevalence of dyslipidaemia varies from region to region, but it is estimated that about half of the adult population…

ACS one of the leading causes of disability in people of all ages

Ischaemic heart disease – now referred to as acute coronary syndrome (ACS) –is ranked second  after neonatal disorders as the…

7 key messages from the ECS about adult CHD

Although the prevalence of severe congenital heart defects (CHD) is declining worldwide, the overall prevalence – especially in adult patients…

Sanofi and Regeneron announce approval of alirocumab for the treatment of hypercholesterolaemia in SA

Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the South African Health Products Regulatory Agency (SAHPRA) has approved alirocumab for…

Acquired haemophilia: Rare, but fatal

Acquired haemophilia A (AHA) – also known as acquired factor VIII inhibitor disorder – is a rare bleeding condition (one…

Increased cardiovascular residual risk in patients with diabetes due to atherogenic dyslipidaemia

Cardiovascular disease (CVD) and type 2 diabetes (T2DM) is on the increase worldwide and clinicians need to be aware of…

BP control crucial to prevent overt HF

More than 7.5 million deaths per year are attributable to hypertension.

Small-dense LDL and triglycerides in atherogenic dyslipidaemia

Cardiovascular disease (CVD) and Type 2 diabetes is on the increase worldwide and clinicians need to be aware of the…

Read More

Vasculitis in the heart: Late complication of COVID-19

A case report has emerged of a 31-year-old woman with heart damage almost two weeks after hospital discharge.

Diuretics for hypertension

Since diuretics are an important treatment for hypertension, they have an important role in the South African healthcare system, where…

Read More

Management of CV risk factors in patients with Covid-19

The Covid-19 causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), affects multiple organ systems, especially the lungs and heart.…

Evolocumab and CVD: What you need to know

Low-density lipoprotein (LDL) cholesterol is a well-established and modifiable risk factor for cardiovascular disease.

Different strategies to prevent and treat VTE in stroke patients

Arrhythmias – often described as ‘hijackers’ of the heart’s rhythm and pump functions, cause the heart to either beat too…

Which dual combinations work best in Black hypertensive patients?

Since the 1980s, systolic blood pressure (SBP) has increased exponentially in Black patients and currently, the highest prevalence of hypertension…

« » page 1 / 4